Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma

Aim: Gemcitabine is a frontline agent for locally-advanced and metastatic pancreatic ductal adenocarcinoma (PDAC), but neither gemcitabine alone nor in combination produces durable remissions of this tumor type. We developed three PDAC patient-derived xenograft (PDX) models with gemcitabine resistan...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Aubrey L., Garcia, Patrick L., Gamblin, Tracy L., Vance, Rebecca B., Yoon, Karina J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561044/
https://www.ncbi.nlm.nih.gov/pubmed/33073205
http://dx.doi.org/10.20517/cdr.2020.35

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561044/
https://www.ncbi.nlm.nih.gov/pubmed/33073205
http://dx.doi.org/10.20517/cdr.2020.35

Ejemplares similares